BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23535553)

  • 1. [New genetic tests and their clinical utility for cancer screening].
    Probst-Hensch NM; Brand A
    Ther Umsch; 2013 Apr; 70(4):251-4; discussion 255-6. PubMed ID: 23535553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
    Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
    Domchek SM; Rebbeck TR
    LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for ovarian cancer prevention.
    Dann RB; Kelley JL; Zorn KK
    Obstet Gynecol Clin North Am; 2007 Dec; 34(4):667-86, viii. PubMed ID: 18061863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genetic test and prophylactic treatment in breast cancer families].
    Miyoshi Y; Noguchi S
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ability to predict breast cancer in Asian women using a polygenic susceptibility model.
    Hartman M; Suo C; Lim WY; Miao H; Teo YY; Chia KS
    Breast Cancer Res Treat; 2011 Jun; 127(3):805-12. PubMed ID: 21153878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Familial breast cancer: what the radiologist needs to know].
    Kuhl CK
    Rofo; 2006 Jul; 178(7):680-7. PubMed ID: 16817122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic changes in breast cancer - an overview].
    Dimitrov G; Iovchev I; Nikolov S
    Khirurgiia (Sofiia); 2000; 56(5-6):60-2. PubMed ID: 11692938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial breast and ovarian cancers.
    Arai M; Utsunomiya J; Miki Y
    Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 susceptibility markers and postmenopausal breast cancer: the Iowa Women's Health Study.
    Thompson JA; Chen PL; King RA; Rich SS; Oetting WS; Armstrong C; Folsom AR; Sellers TA
    Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):507-11. PubMed ID: 10815696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial non-BRCA1/BRCA2-associated breast cancer.
    Eccles DM; Pichert G
    Lancet Oncol; 2005 Sep; 6(9):705-11. PubMed ID: 16129371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.
    Heisey RE; Carroll JC; Warner E; McCready DR; Goel V
    Can Fam Physician; 1999 Jan; 45():114-24. PubMed ID: 10889864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
    Roukos DH; Briasoulis E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cancer genetics: estimation of the needs of the population in France for the next ten years].
    Bonaïti-Pellié C; Andrieu N; Arveux P; Bonadona V; Buecher B; Delpech M; Jolly D; Julian-Reynier C; Luporsi E; Noguès C; Nowak F; Olschwang S; Orsi F; Pujol P; Saurin JC; Sinilnikova O; Stoppa-Lyonnet D; Thépot F
    Bull Cancer; 2009 Sep; 96(9):875-900. PubMed ID: 19751997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
    Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic predisposition syndromes and their management.
    Euhus DM; Robinson L
    Surg Clin North Am; 2013 Apr; 93(2):341-62. PubMed ID: 23464690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.